What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “JSKN003 (6.3 mg/kg) was administered intravenously on the first day of each cycle, once every 3 weeks (Q3W).”In the company’s words, NCT07384377 on ClinicalTrials.gov
- Tested for
- Breast Cancer, Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants, Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancers, HER2-positive Colorectal Cancer, HER2-positive Recurrent or Metastatic Breast Cancer, HER2-positive Gastric Cancer and 1 more
- Main trialPhase 3
- “This study is a randomized controlled, open-label, multicenter phase III clinical study evaluating the efficacy and safety of chemotherapy selected by investigator JSKN003 s in subjects with recurrent or metastatic breast cancer who have previously failed first- or second-line chemotherapy in subjects with recurrent or metastatic breast cancer who have failed prior first- or second-line chemotherapy. The study planned to enroll 408 subjects in a 1:1 ratio and stratified block randomization method assigned to: * Experimental group: JSKN003 monotherapy * Control group: investigator's chosen…”In the company’s words, NCT06079983 on ClinicalTrials.gov
Other drugs for Breast Cancer
- D-0502InventisBio Co., Ltd · Phase 3
- ElacestrantStemline Therapeutics, Inc. · Phase 3
- YL202MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- SPH4336Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- NiraparibGSK · Phase 3
Coming up4
- 30 DecPhase 3 trial completes · ClinicalTrials.gov
- 29 May 2027Phase 2 trial completes · ClinicalTrials.gov
- 30 Nov 2027Phase 3 trial completes · ClinicalTrials.gov
- 30 Jun 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 1 Apr 2026 | JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects | |
| Phase 3Recruiting | 13 Oct 2026 | JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer | |
| Phase 3Not yet recruiting | 30 Dec 2026 | JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer | |
| Phase 3Not yet recruiting | 30 Nov 2027 | JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan | |
| Phase 2Not yet recruiting | 29 May 2027 | A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer | |
| Phase 2Not yet recruiting | 30 Jun 2028 | JSKN003 Combined Treatment of HER2-positive Gastric Cancer | |
| Phase 1/2Active, not recruiting | 30 Jul 2026 | Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors | |
| Phase 1Completed | 15 Apr 2025 | First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026